EUVIMEDEUVIMED entdecken
Open Access · CC0

Androgen receptor and its correlation with estrogen and progesterone receptors, aimed for identification of cases for future anti-androgen therapy in endometrial cancers

Neda A Moatamed iD, Saba Vahdatshariatpanahi iD, David W Gjertson, Chana R Sachs, Yuna Kang iD, Nora Ostrzega, Jiaoti Huang, Sanaz Memarzadeh

PLOS ONE · 2023

DOI: 10.1371/journal.pone.0291361 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Neda A Moatamed und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, United States of America. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Carcinoma, Endometrioid. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC0). Gefördert von: VA Greater Los Angeles Healthcare System.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The expression of androgen receptor (AR) is not commonly tested or studied in uterine cancers, unlike estrogen receptor (ER) and progesterone receptor (PR) which are positive in most endometrial carcinomas. In this series, we evaluated the expression of AR and its comparison to ER and PR in different types of endometrial cancers and have reviewed the literature. Materials and methods The status of AR, ER, and PR expression were evaluated in 71 cases which were categorized into endometrial endometrioid cancer (EEC), non-endometrioid endometrial cancers (NEEC), and metastatic carcinomas of endometrium. Expression of the receptors were compared to each other as well as to mismatch repair proteins (MMR), p53, and body mass index (BMI) using Fisher’s Exact test in the StatPlus software.

Results

In EECs, the positivity was 97% for all the three receptors. In NEEC, positivity rates were 68%, 48%, and 35% for AR, ER, and PR respectively. In Metastatic carcinomas, AR and ER positivity was seen in 100% while PR was positive in 75% of the cases. In all cancers, the rates were 17% (11/66) for MMR loss, 57% (30/53) for p53 aberrant expression, and 76% (54/71) for the patients with BMI of ≥ 25 (kg/m2).

Conclusion

AR is expressed in a high percentage of endometrial cancers. Its significance is more evident in high-grade NEEC where ER and PR may not be expressed. These findings warrant further evaluation of AR expression and candidacy of this pathway as a potential therapeutic target in endometrial cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endometrial NeoplasmsCarcinoma, EndometrioidFemaleHumansReceptors, ProgesteroneReceptors, AndrogenTumor Suppressor Protein p53EstrogensReceptors, Estrogen

Substanzen

Receptors, ProgesteroneReceptors, AndrogenTumor Suppressor Protein p53EstrogensReceptors, Estrogen

Autor:innen und Institutionen

  • Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, United States of America.
  • Department of Biostatistics, Fielding School of Public Health at UCLA, Los Angeles, California, United States America.
  • Department of Pathology, Duke University School of Medicine, Durham, North Carolina, United States of America.
  • Department of Obstetrics and Gynecology, David Geffen School of Medicine at UCLA, Los Angeles, California, United States of America.
  • UCLA Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California Los Angeles, Los Angeles, California, United States America.
  • Johnson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California, United States of America.

ORCID-Profile: Neda A Moatamed, Saba Vahdatshariatpanahi, Yuna Kang

Förderung

  • VA Greater Los Angeles Healthcare System

Zitieren

APA

Moatamed, N. A., Vahdatshariatpanahi, S., Gjertson, D. W., Sachs, C. R., Kang, Y., Ostrzega, N., Huang, J., & Memarzadeh, S. (2023). Androgen receptor and its correlation with estrogen and progesterone receptors, aimed for identification of cases for future anti-androgen therapy in endometrial cancers. PLOS ONE. https://doi.org/10.1371/journal.pone.0291361

Vancouver

Moatamed NA, Vahdatshariatpanahi S, Gjertson DW, Sachs CR, Kang Y, Ostrzega N, et al. Androgen receptor and its correlation with estrogen and progesterone receptors, aimed for identification of cases for future anti-androgen therapy in endometrial cancers. PLOS ONE. 2023. doi:10.1371/journal.pone.0291361

BibTeX
@article{Moatamed2023,
  author = {Moatamed, Neda A and Vahdatshariatpanahi, Saba and Gjertson, David W and Sachs, Chana R and Kang, Yuna and Ostrzega, Nora and Huang, Jiaoti and Memarzadeh, Sanaz},
  title = {Androgen receptor and its correlation with estrogen and progesterone receptors, aimed for identification of cases for future anti-androgen therapy in endometrial cancers},
  journal = {PLOS ONE},
  year = {2023},
  doi = {10.1371/journal.pone.0291361}
}
Kostenlos starten →